64th Annual Meeting of the Japanese Society of Neurology

64th Annual Meeting of the Japanese Society of Neurology

May 31 - Jun 3, 2023Makuhari Messe
Annual Meeting of the Japanese Society of Neurology
64th Annual Meeting of the Japanese Society of Neurology

64th Annual Meeting of the Japanese Society of Neurology

May 31 - Jun 3, 2023Makuhari Messe

[HT-05-4]Issues in clinical trials of disease-modifying therapies for Parkinson's disease

Thomas Foltynie1,2(1.UCL Institute of Neurology, UK, 2.National Hospital for Neurology & Neurosurgery, UK)
photo
Professor Tom Foltynie is Professor of Neurology in the Department of Clinical and Movement Neurosciences, UCL Institute of Neurology and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London. He is responsible for Movement disorder patients, particularly Parkinson’s disease (PD) patients undergoing advanced treatments such as Deep Brain Stimulation (DBS), Apomorphine and Duodopa. He is chief investigator for a series of trials of Exenatide- a potential neurorestorative treatment for PD, and has been UCL’s PI for multi-centre trials of gene therapy and cell therapy as potential neurorestorative approaches for PD. He is the chief investigator for the Edmond J Safra Accelerating Clinical trials in PD project which will establish a platform for the testing of multiple potential neuroprotective approaches simultaneously in the UK.

Password required to view

Abstract password authentication.
You can find the password on page 13 of the program book.